TLR2 agonist (Innavac)

N/A

Report date: 2025/03/20 20:00:06
NME

Base Information

Drug NameTLR2 agonist (Innavac)
Drug Alias NamePam2CysTLR2 agonist (University of Melbourne/UoM Commercial/Bio Farma)TLR2 agonist (University of Melbourne/UoM Commercial)
ClassificationSmall molecules > Lipid
Mechanisms of ActionToll like receptor 2 agonists
TargetsToll like receptor 2
Therapy Area/IndicationsVaccinationInfluenza, HumanCommunicable Diseases
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryAustralia and New ZealandIndonesia
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesUniversity Of Melbourne
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesUoM Commercial LtdAxelia Oncology Pty LtdPt Bio Farma +[4] 
Active IndicationsN/A
Inactive IndicationsVaccinationInfluenza, HumanCommunicable Diseases

Other Information

ATC CodeN/A
Related LinksN/A